Messenger Ribonucleic Acid (MRNA) Manufacturing Service Market Report 2026

The messenger ribonucleic acid (mrna) manufacturing service market size has grown rapidly in recent years. It will grow from $6.14 billion in 2025 to $7.12 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to rise of mrna therapeutics research, vaccine emergency manufacturing demand, limited in house mrna capacity, growth of cdmo partnerships, expansion of biotech pipelines.

The messenger ribonucleic acid (mrna) manufacturing service market size is expected to see rapid growth in the next few years. It will grow to $12.97 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to increase in mrna therapy trials, expansion of contract manufacturing demand, growth in personalized medicine, higher outsourcing by biotech firms, scale up of commercial mrna products. Major trends in the forecast period include integrated mrna process development services, large scale in vitro transcription production, end to end lnp encapsulation services, rapid technology transfer programs, gmp grade mrna batch manufacturing.

The growing clinical trial activity is projected to boost the messenger ribonucleic acid (mRNA) manufacturing service market in the coming period. Clinical trial activity encompasses all processes involved in planning, conducting, and managing clinical studies to assess medical interventions in humans. This activity is rising due to the adoption of digital and decentralized trial models, which allow quicker patient enrollment, remote monitoring, and more efficient data collection across larger populations. Messenger ribonucleic acid (mRNA) manufacturing services facilitate clinical trial activity by providing rapid and adaptable production of mRNA-based therapies, ensuring timely supply for various trial stages and accelerating drug development. For instance, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade organization, reported that the number of industry-initiated clinical trials in the UK rose to 426 in 2023, up from 411 in 2022. Therefore, the growing clinical trial activity is driving the expansion of the messenger ribonucleic acid (mRNA) manufacturing service market.

Leading companies operating in the messenger ribonucleic acid (mRNA) manufacturing service market are focusing on developing innovative solutions, such as in vitro transcription (IVT), to accelerate the production of high-quality, clinical-grade mRNA for vaccines and personalized therapies. In vitro transcription (IVT) refers to a laboratory process that synthesizes messenger RNA (mRNA) from a DNA template using RNA polymerase enzymes, enabling the production of mRNA outside of living cells for research, therapeutic, or vaccine applications. For example, in May 2025, GenScript Biotech Corporation, a China-based biotechnology company, launched a GMP-like mRNA manufacturing service to support preclinical studies and IND-enabling research. The solution provides high-purity, scalable in vitro transcription (IVT) processes with stringent control over critical quality attributes such as capping efficiency, poly(A) tail length, and impurity profiles. It supports rapid transition from preclinical to clinical stages by enabling consistent batch-to-batch production, flexible customization for different mRNA constructs, and reduced development timelines. In addition, the GMP-like framework ensures regulatory readiness through enhanced traceability, standardized workflows, and comprehensive quality documentation, helping developers de-risk later-stage manufacturing and accelerate clinical progress.

In December 2025, BioNTech SE, a Germany-based biotechnology company, acquired CureVac N.V. for an undisclosed sum. With this acquisition, BioNTech intends to reinforce its distinctive position in the mRNA sector by bringing CureVac onboard to enhance mRNA design, delivery, manufacturing, and commercialization capabilities, particularly advancing oncology initiatives such as cancer immunotherapies and BNT327. CureVac N.V. is a Germany-based company that offers mRNA development and manufacturing services for therapeutic and vaccine purposes.

Major companies operating in the messenger ribonucleic acid (mrna) manufacturing service market are Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Biotechnologies, Evonik Industries AG, Lonza Group AG, Charles River Laboratories International Inc., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Recipharm AB, Curia Global Inc., Emergent BioSolutions Inc., AGC Biologics Inc., Corden Pharma International GmbH, Rentschler Biopharma SE, GenScript ProBio, ST Pharm Co. Ltd., etherna Immunotherapies NV, BIOMAY AG., Porton Advanced Solutions Ltd., Wacker Biotech GmbH.

Tariffs on specialized bioreactors, filtration systems, nucleic acid synthesis inputs, and cold chain logistics equipment are impacting the mrna manufacturing service market by raising setup and operating costs. Manufacturing and fill finish service segments are most exposed where imported process equipment and reagents are essential, particularly across north america and europe. Higher input costs can increase contract pricing and project budgets for clients. However, tariffs are also promoting domestic production of key materials and regional manufacturing hubs. This creates positive opportunities for local mrna service providers and equipment suppliers.

The messenger ribonucleic acid (mrna) manufacturing service market research report is one of a series of new reports that provides messenger ribonucleic acid (mrna) manufacturing service market statistics, including messenger ribonucleic acid (mrna) manufacturing service industry global market size, regional shares, competitors with a messenger ribonucleic acid (mrna) manufacturing service market share, detailed messenger ribonucleic acid (mrna) manufacturing service market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mrna) manufacturing service industry. This messenger ribonucleic acid (mrna) manufacturing service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Messenger ribonucleic acid (mRNA) manufacturing service refers to contract-based or in-house services that produce high-quality mRNA molecules for therapeutic or vaccine purposes. These services encompass the design, synthesis, purification, and quality control of mRNA, often customized for lipid nanoparticle delivery systems. They enable the creation of safe and effective mRNA-based therapeutics and vaccines for research, clinical trials, and commercial distribution.

The core service types of messenger ribonucleic acid (mRNA) manufacturing services encompass process development, analytical testing, manufacturing, fill-finish, and other related services. Process development includes services aimed at optimizing and scaling mRNA production processes for research, clinical trials, and commercial purposes. Operational scales cover research and preclinical scale, clinical scale, and commercial scale. Applications include vaccines, therapeutics, research, and other related areas, with end users being pharmaceutical and biotechnology companies, academic and research institutions, and other relevant organizations.

The messenger ribonucleic acid (mRNA) manufacturing service market includes revenues earned by entities through the regulatory support, technology transfer, supply chain management, design and synthesis, purification, scale-up services, encapsulation services, plasmid production, quality control testing, product characterization services, formulation development, lipid nanoparticle (LNP) formulation services, and cold chain logistics services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.